Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026)

Nurix Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 55.32% for Q1 2026.

  • Quarterly Return on Capital Employed fell 1355.0% to 55.32% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 55.32% through Feb 2026, down 1355.0% year-over-year, with the annual reading at 48.23% for FY2025, 290.0% up from the prior year.
  • Return on Capital Employed was 55.32% for Q1 2026 at Nurix Therapeutics, roughly flat from 55.06% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 34.79% in Q1 2022 and troughed at 63.82% in Q1 2024.
  • The 5-year median for Return on Capital Employed is 54.1% (2024), against an average of 51.33%.
  • Year-over-year, Return on Capital Employed crashed -2621bps in 2022 and then soared 2205bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 50.05% in 2022, then fell by -26bps to 63.31% in 2023, then soared by 32bps to 42.98% in 2024, then fell by -28bps to 55.06% in 2025, then dropped by 0bps to 55.32% in 2026.
  • Per Business Quant, the three most recent readings for NRIX's Return on Capital Employed are 55.32% (Q1 2026), 55.06% (Q4 2025), and 56.3% (Q3 2025).